Limits...
Effect of deamino-8-D-arginine desmopressin in uremic bleeding.

Hong SY, Yang DH - Korean J. Intern. Med. (1996)

Bottom Line: Cessation of the oozing did not occur within 3 hours after DDAVP administration in all of the cases. vWF levels and t-PA antigen were significantly increased after DDAVP administration peaked at 30 min for vWF and 60 min for t-PA antigen. t-PA activity increased in 6 cases and euglobulin fibrinolytic activity increased in 7 cases, respectively.DDAVP increased both vWF and t-PA levels and cessation of the oozing from post-operative AV-fistula wounds did not occur within 3 hours after DDAVP administration in all of the cases.These results suggest that the effect of DDAVP should be reassessed in the treatment of uremic bleeding.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Soonchunhyang Hospital, Chunan, Korea.

ABSTRACT

Objectives: This study is designed to evaluate the clinical outcome of uremic bleeding treated with DDAVP. DDAVP was given intravenously in nine ESRD patients who had undergone A/V fistula surgery and showed oozing of the operation site for more than one hour.

Methods: Hemostasis was observed by removing the blood from the wound site with a piece of filter paper for 3 hours after DDAVP administration. vWF, t-PA antigen, t-PA activity, total fibrinolytic activity in euglobulin fraction, fibrinopeptide A and FDP were measured before and after DDAVP administration.

Results: Cessation of the oozing did not occur within 3 hours after DDAVP administration in all of the cases. vWF levels and t-PA antigen were significantly increased after DDAVP administration peaked at 30 min for vWF and 60 min for t-PA antigen. t-PA activity increased in 6 cases and euglobulin fibrinolytic activity increased in 7 cases, respectively. These values fell towards pre-administration levels 120 min after the administration. There was no difference in fibrinopeptide A levels before and after DDAVP administration. FDP became positive in 4 cases after DDAVP administration.

Conclusion: DDAVP increased both vWF and t-PA levels and cessation of the oozing from post-operative AV-fistula wounds did not occur within 3 hours after DDAVP administration in all of the cases. These results suggest that the effect of DDAVP should be reassessed in the treatment of uremic bleeding.

Show MeSH

Related in: MedlinePlus

Individual changes of t-PA antigen before and after DDAVP administration.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4532022&req=5

f2-kjim-11-2-145-8: Individual changes of t-PA antigen before and after DDAVP administration.

Mentions: t-PA antigen level was significantly increased after DDAVP administration, from 3,7±0.8 μg/ml (range; 2.3–5.4 μg/ml) to 9.5±3.9 μg/ml(range; 5.3–15 μg/ml) (p<0.01) before and 60 min following DDAVP administration, respectively (Fig. 2).


Effect of deamino-8-D-arginine desmopressin in uremic bleeding.

Hong SY, Yang DH - Korean J. Intern. Med. (1996)

Individual changes of t-PA antigen before and after DDAVP administration.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4532022&req=5

f2-kjim-11-2-145-8: Individual changes of t-PA antigen before and after DDAVP administration.
Mentions: t-PA antigen level was significantly increased after DDAVP administration, from 3,7±0.8 μg/ml (range; 2.3–5.4 μg/ml) to 9.5±3.9 μg/ml(range; 5.3–15 μg/ml) (p<0.01) before and 60 min following DDAVP administration, respectively (Fig. 2).

Bottom Line: Cessation of the oozing did not occur within 3 hours after DDAVP administration in all of the cases. vWF levels and t-PA antigen were significantly increased after DDAVP administration peaked at 30 min for vWF and 60 min for t-PA antigen. t-PA activity increased in 6 cases and euglobulin fibrinolytic activity increased in 7 cases, respectively.DDAVP increased both vWF and t-PA levels and cessation of the oozing from post-operative AV-fistula wounds did not occur within 3 hours after DDAVP administration in all of the cases.These results suggest that the effect of DDAVP should be reassessed in the treatment of uremic bleeding.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Soonchunhyang Hospital, Chunan, Korea.

ABSTRACT

Objectives: This study is designed to evaluate the clinical outcome of uremic bleeding treated with DDAVP. DDAVP was given intravenously in nine ESRD patients who had undergone A/V fistula surgery and showed oozing of the operation site for more than one hour.

Methods: Hemostasis was observed by removing the blood from the wound site with a piece of filter paper for 3 hours after DDAVP administration. vWF, t-PA antigen, t-PA activity, total fibrinolytic activity in euglobulin fraction, fibrinopeptide A and FDP were measured before and after DDAVP administration.

Results: Cessation of the oozing did not occur within 3 hours after DDAVP administration in all of the cases. vWF levels and t-PA antigen were significantly increased after DDAVP administration peaked at 30 min for vWF and 60 min for t-PA antigen. t-PA activity increased in 6 cases and euglobulin fibrinolytic activity increased in 7 cases, respectively. These values fell towards pre-administration levels 120 min after the administration. There was no difference in fibrinopeptide A levels before and after DDAVP administration. FDP became positive in 4 cases after DDAVP administration.

Conclusion: DDAVP increased both vWF and t-PA levels and cessation of the oozing from post-operative AV-fistula wounds did not occur within 3 hours after DDAVP administration in all of the cases. These results suggest that the effect of DDAVP should be reassessed in the treatment of uremic bleeding.

Show MeSH
Related in: MedlinePlus